PE20152007A1 - Entidades quimicas - Google Patents

Entidades quimicas

Info

Publication number
PE20152007A1
PE20152007A1 PE2015001900A PE2015001900A PE20152007A1 PE 20152007 A1 PE20152007 A1 PE 20152007A1 PE 2015001900 A PE2015001900 A PE 2015001900A PE 2015001900 A PE2015001900 A PE 2015001900A PE 20152007 A1 PE20152007 A1 PE 20152007A1
Authority
PE
Peru
Prior art keywords
heteroaryl
aryl
compounds
treatment
chemical entities
Prior art date
Application number
PE2015001900A
Other languages
English (en)
Inventor
Munoz David Alvaro Cebrian
Soler Maria Nieto
Oliver Renner
Contreras Andres Joaquin Lopez
Busto Carmen Varela
Costa Matilde Murga
Aristegui Sonsoles Rodriguez
Lazaro Luis Ignacio Toledo
Ferreira Maria Del Rosario Rico
Aparicio Carmen Blanco
Fernandez Joaquin Pastor
Gonzalez Sonia Martinez
Ruiz Oscar Fernandez-Capetillo
Original Assignee
Fundacion Ct De Investigaciones Oncologicas Carlos Iii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48013903&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20152007(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fundacion Ct De Investigaciones Oncologicas Carlos Iii filed Critical Fundacion Ct De Investigaciones Oncologicas Carlos Iii
Publication of PE20152007A1 publication Critical patent/PE20152007A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

Referida a compuestos triciclicos de formula (I), en donde R1 es arilo o heteroarilo, R2 es NR3S=2R3, alquilo, cicloalquilo, arilo o heteroarilo y m es 1 o 2; asi como a sus sales, solvatos y estereoisomeros farmaceuticamente aceptables de los mismos. Estos compuestos son inhibidores de cinasa de ataxia telangiectasia mutada y relacionada con Rad3 (ATR) y son potencialmente utiles en el tratamiento del cancer, principalmente de pulmon, prostata, melanoma, ovario, mama, endometrio, entre otros. Tambien esta referida a composiciones farmaceuticas, productos de combinacion y procedimientos de tratamiento que usan estas composiciones
PE2015001900A 2013-03-15 2014-03-14 Entidades quimicas PE20152007A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13382089 2013-03-15

Publications (1)

Publication Number Publication Date
PE20152007A1 true PE20152007A1 (es) 2016-02-04

Family

ID=48013903

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015001900A PE20152007A1 (es) 2013-03-15 2014-03-14 Entidades quimicas

Country Status (32)

Country Link
US (1) US9453031B2 (es)
EP (1) EP2970332B1 (es)
JP (1) JP6379115B2 (es)
KR (1) KR102206318B1 (es)
CN (1) CN105051047B (es)
AR (1) AR095443A1 (es)
AU (1) AU2014229735B2 (es)
BR (1) BR112015023060B1 (es)
CA (1) CA2904768C (es)
CL (1) CL2015002591A1 (es)
CY (1) CY1120619T1 (es)
DK (1) DK2970332T3 (es)
EA (1) EA029771B1 (es)
ES (1) ES2670674T3 (es)
HK (1) HK1215021A1 (es)
HR (1) HRP20180839T1 (es)
HU (1) HUE037685T2 (es)
IL (1) IL240708B (es)
LT (1) LT2970332T (es)
MX (1) MX368056B (es)
NO (1) NO2970332T3 (es)
NZ (1) NZ711038A (es)
PE (1) PE20152007A1 (es)
PH (1) PH12015502159B1 (es)
PL (1) PL2970332T3 (es)
PT (1) PT2970332T (es)
RS (1) RS57216B1 (es)
SG (1) SG11201507555PA (es)
SI (1) SI2970332T1 (es)
TW (1) TWI557131B (es)
UA (1) UA118261C2 (es)
WO (1) WO2014140644A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014110574A1 (en) 2013-01-14 2014-07-17 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
SG10201705662WA (en) 2013-01-15 2017-08-30 Incyte Corp Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
PE20160532A1 (es) 2013-08-23 2016-05-21 Incyte Corp Compuesto de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
WO2016112374A2 (en) * 2015-01-09 2016-07-14 The General Hospital Corporation Treating cancer using inhibitors of ataxia-telangiectasia mutated and rad3-related (atr)
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物
ES2788348T3 (es) * 2016-05-24 2020-10-21 Merck Patent Gmbh Derivados heterocíclicos tricíclicos
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
JP7290651B2 (ja) * 2018-02-07 2023-06-13 ウーシー・バイオシティ・バイオファーマシューティクス・カンパニー・リミテッド Ａｔｒ阻害剤及びその応用
WO2020094084A1 (zh) * 2018-11-07 2020-05-14 南京明德新药研发有限公司 作为ret抑制剂的三并环衍生物
CN113004303A (zh) * 2019-12-18 2021-06-22 江苏恒瑞医药股份有限公司 嘧啶并噁嗪类三环衍生物、其制备方法及其在医药上的应用
TW202140474A (zh) * 2020-01-17 2021-11-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合雜芳基類衍生物、其製備方法及其在醫藥上的應用
AU2021360636A1 (en) 2020-10-16 2023-06-15 Shanghai De Novo Pharmatech Co., Ltd. Triheterocyclic derivative, and pharmaceutical composition and application thereof
CN115466258A (zh) * 2021-06-11 2022-12-13 成都苑东生物制药股份有限公司 Atr抑制剂及其用途
CN115286645A (zh) * 2022-08-16 2022-11-04 南京雷正医药科技有限公司 三环杂环衍生物及其药物组合物和用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
WO1993014080A1 (en) * 1992-01-15 1993-07-22 E.I. Du Pont De Nemours And Company Bridged heterocyclic fungicides
JPH08336393A (ja) 1995-04-13 1996-12-24 Mitsubishi Chem Corp 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法
EP0961780B1 (en) 1997-02-12 2007-04-11 Electrophoretics Limited Protein markers for lung cancer and use thereof
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
KR20080015482A (ko) 1999-02-10 2008-02-19 아스트라제네카 아베 혈관형성 억제제로서의 퀴나졸린 유도체
US7173038B1 (en) 1999-11-05 2007-02-06 Astrazeneca Ab Quinazoline derivatives as VEGF inhibitors
WO2001060814A2 (en) 2000-02-15 2001-08-23 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
CN1431999A (zh) 2000-05-31 2003-07-23 阿斯特拉曾尼卡有限公司 具有血管损伤活性的吲哚衍生物
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
CN1255391C (zh) 2000-07-07 2006-05-10 安吉奥金尼药品有限公司 作为血管破坏剂的colchinol衍生物
MXPA02012903A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como inhibidores de angiogenesis.
US8735411B2 (en) * 2006-10-02 2014-05-27 Abbvie Inc. Macrocyclic benzofused pyrimidine derivatives
WO2008052733A1 (en) * 2006-10-30 2008-05-08 Novartis Ag Imidazopyridazines as pi3k lipid kinase inhibitors
AU2008250328A1 (en) * 2007-05-09 2008-11-20 Novartis Ag Substituted imidazopyridazines as PI3K lipid kinase inhibitors
PL2467387T3 (pl) * 2009-08-20 2015-08-31 Karus Therapeutics Ltd Tricykliczne związki heterocykliczne jako inhibitory kinazy 3-fosfoinozytydu
CN102020657A (zh) * 2009-09-11 2011-04-20 上海艾力斯医药科技有限公司 稠合杂芳基衍生物、制备方法及其应用
US8623869B2 (en) * 2010-06-23 2014-01-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
NZ609448A (en) * 2010-12-16 2015-07-31 Hoffmann La Roche Tricyclic pi3k inhibitor compounds and methods of use

Also Published As

Publication number Publication date
JP6379115B2 (ja) 2018-08-22
IL240708B (en) 2019-08-29
AU2014229735A1 (en) 2015-09-03
US9453031B2 (en) 2016-09-27
CL2015002591A1 (es) 2016-02-05
BR112015023060A2 (pt) 2017-07-18
SG11201507555PA (en) 2015-10-29
JP2016510803A (ja) 2016-04-11
HK1215021A1 (zh) 2016-08-12
US20160024112A1 (en) 2016-01-28
EA029771B1 (ru) 2018-05-31
MX368056B (es) 2019-09-18
CA2904768C (en) 2021-07-27
RS57216B1 (sr) 2018-07-31
MX2015011549A (es) 2016-05-31
CA2904768A1 (en) 2014-09-18
PH12015502159A1 (en) 2016-01-25
TWI557131B (zh) 2016-11-11
DK2970332T3 (en) 2018-05-22
NZ711038A (en) 2020-02-28
PL2970332T3 (pl) 2018-08-31
PH12015502159B1 (en) 2016-01-25
UA118261C2 (uk) 2018-12-26
AR095443A1 (es) 2015-10-14
CY1120619T1 (el) 2019-12-11
SI2970332T1 (en) 2018-06-29
TW201446772A (zh) 2014-12-16
EA201591781A1 (ru) 2016-02-29
CN105051047B (zh) 2017-12-15
IL240708A0 (en) 2015-10-29
AU2014229735B2 (en) 2018-08-09
CN105051047A (zh) 2015-11-11
LT2970332T (lt) 2018-06-11
HRP20180839T1 (hr) 2018-06-29
ES2670674T3 (es) 2018-05-31
KR102206318B1 (ko) 2021-01-25
EP2970332B1 (en) 2018-02-28
HUE037685T2 (hu) 2018-09-28
KR20150129741A (ko) 2015-11-20
BR112015023060B1 (pt) 2022-07-05
EP2970332A1 (en) 2016-01-20
WO2014140644A1 (en) 2014-09-18
NO2970332T3 (es) 2018-07-28
PT2970332T (pt) 2018-05-25

Similar Documents

Publication Publication Date Title
PE20152007A1 (es) Entidades quimicas
ECSP22091792A (es) Compuestos tricíclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroplastos
CL2017000521A1 (es) Inhibidores de desmetilasa-1 específica a lisina
CL2012000324A1 (es) Compuestos derivados de benciimidazol sustituido con un grupo pirazol sustituido, inhibidor de quinasa fgfr; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
CL2015003491A1 (es) Compuestos químicos.
UY35898A (es) ?compuestos inhibidores de syk y composiciones que los comprenden?.
CO2017000362A2 (es) Compuestos de derivados heterocíclicos sustituidos como inhibidores de demtilasa-1 específica lisina
CU24605B1 (es) Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2
UY35975A (es) Macrociclos con grupos p2? heterocíclicos como inhibidores del factor xia
CL2015001508A1 (es) Compuestos derivados de bencimidazol, antagonistas de receptores ep4; composicion farmaceutica; combinacion farmaceutica; uso para tratar y/o prevenir enfermedades tales como endometriosis, hemorragias uterinas, dismenorrea, canceres de pulmon, de intestino, de mama, de prostata, entre otros.
CR20150368A (es) Inhibidores de histona desmetilasa
ECSP088820A (es) Síntesis de acil-amino-alquenilen-amidas utiles como antagonistas de la sustancia p.
UY34825A (es) Síntesis de compuestos heterocíclicos
UY34393A (es) Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor xia
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
PH12017502334A1 (en) Polycyclic amide derivative as cdk9 inhibitors
PE20141381A1 (es) Terapia de combinacion que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cancer
EA201992183A3 (ru) Синтез полициклических карбамоилпиридоновых соединений
CL2015001246A1 (es) Derivados de bendamustina y los metodos de su uso
UY31689A1 (es) Derivados de platino-carbeno n-heterocíclico, su preparación y su aplicación en terapéutica
SV2009003389A (es) Compuestos de pirido [2,3-d] pirimidina-7-ona como inhibidores de p13k-alfa para el tratamiento del cancer
CL2019000662A1 (es) Inhibidores de dopamina–b–hidroxilasa.
CY1120142T1 (el) Ενωσεις αζετιδινυλοξυφαινυλοπυρρολiδινης
MX2018001576A (es) Piridinas y su uso en el tratamiento del cancer.
NI201600163A (es) Derivados de diheterociclo enlazado a cicloalquilo

Legal Events

Date Code Title Description
FG Grant, registration